Galeterone

Key Product Details

Product Description

Galeterone is a CYP17 inhibitor (IC₅₀ = 300 nM) and androgen receptor antagonist (IC₅₀ = 384 nM in PC3-AR cells). Inhibits DHT-stimulated prostate cancer cell proliferation in vitro. Exhibits antitumor activity in SCID mice bearing prostate cancer xenografts.

Product Specifications for Galeterone

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Galeterone

The following data is based on the product molecular weight 388.55.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	5.15 mL	25.74 mL	51.47 mL
2.5 mM	1.03 mL	5.15 mL	10.29 mL
5 mM	0.51 mL	2.57 mL	5.15 mL
25 mM	0.10 mL	0.51 mL	1.03 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Handratta Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J.Med.Chem. 2005 PMID: 15828836
• Njar & Brodie Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J.Med.Chem. 2015 PMID: 25591066

Product Documents for Galeterone